For the first time, the Inflation Reduction Act (IRA) provides Medicare the ability to directly negotiate maximum fair prices (MFP) of certain high expenditure, single source drugs without generic or biosimilar competition through the Medicare Drug Price Negotiation Program (MDPNP). As we approach the first round of MFPs going into effect January 1, 2026, having a market-wide process to effectuate these MFPs efficiently and accurately is crucial to the success of the program and enabling patient access to the medications they need.

That is why we are currently building an innovative, prospective solution that will assist manufacturers in implementing more efficient MFP refunds, as required by the IRA, by streamlining the gathering of claims and 340B data, calculating MFP refunds, reconciling accounts, and transmitting data to pharmacies and manufacturers.

At this time, we are looking for impacted sites of care who are interested in taking part in our initial pilot group to help us build the most effective solution possible. If interested, we ask that you complete the short form below and a member of our team will reach out to you soon.